Clinical trials recruiting for Stage III Pancreatic Cancer AJCC v8
14
Recruiting trials
51
US states with sites
2
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 8 |
| Illinois | 6 |
| Oregon | 6 |
| Florida | 5 |
| Kentucky | 5 |
| Missouri | 5 |
| Pennsylvania | 5 |
| Wisconsin | 5 |
| Colorado | 4 |
| Connecticut | 4 |
| Georgia | 4 |
| Michigan | 4 |
Top cities
Portland, Oregon 6Chicago, Illinois 5Lexington, Kentucky 5Sacramento, California 5Atlanta, Georgia 4Pittsburgh, Pennsylvania 4Baltimore, Maryland 3Buffalo, New York 3Cincinnati, Ohio 3Columbus, Ohio 3
Self-screener
Recruiting trials
- A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
- AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
- CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
- Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
- Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
- OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Related conditions
Trials recruiting for Stage III Pancreatic Cancer AJCC v8 often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Stage IV Pancreatic Cancer AJCC v8 19Stage II Pancreatic Cancer AJCC v8 9Metastatic Pancreatic Adenocarcinoma 10Unresectable Pancreatic Adenocarcinoma 4Metastatic Pancreatic Carcinoma 8Locally Advanced Pancreatic Adenocarcinoma 16Borderline Resectable Pancreatic Ductal Adenocarcinoma 7Advanced Malignant Solid Neoplasm 13Unresectable Malignant Solid Neoplasm 8
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Stage III Pancreatic Cancer AJCC v8 trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.